glp-1 kidney outcomes news today Glucagon-like peptide-1 receptor agonists in diabetic disease: A review of their kidney and heart protection Cardiovascular, mortality, and kidney outcomes

In the past year, there was news about the prevention of progression to diabetes with tirzepatide (Mounjaro/Zepbound, Eli Lilly), benefits of tirzepatide and semaglutide (Ozempic/Wegovy, Novo Nordisk) in other patient populations such as those with heart failure and chronic kidney disease, and mounting evidence for the triple-hormone agonist retatrutide (Eli Lilly)

Lean proteins : Incorporate sources like chicken, fish, tofu, and legumes to help maintain muscle mass and promote weight loss in the thyroid

2016;310(10):R885895

In real practice, obesity treatment is not about choosing the drug with the biggest average weight-loss number, the physician said, asking not to be named

Our research indicates GLP1s could reduce mortality in the US by up to 6% by 2045, signaling a potential shift after years of slowing life expectancy gains linked to rising obesity and metabolic ill health

About Drugwatch.com 17 Years of Advocacy $324 Million Recovered for Clients 20,000 Families Helped A+ BBB Rating 4.9 Stars from Google Reviews Testimonials I found Drugwatch to be very helpful with finding the right lawyers